Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2023

Genmab — Juni 2023

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #105

    Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #106

      Link Preview Image
      Dansk begejstring over FDA-godkendelse af epcoritamab: Det er et stort fremskridt

      De amerikanske lægemiddelmyndigheder FDA har godkendt det bispecifikke antistof epcoritamab til behandling af patienter med relaps eller refraktært (r/r) storce

      favicon

      (haematologisktidsskrift.dk)

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #107

        God og grundig artikel, der belyser “styrkeforholdet” epco/glofi/car-t.

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Pensionisten
          wrote on sidst redigeret af
          #108

          Tak for den gode artikel, @Bulder. Den var til at forstå - selv for mig! Og det siger ikke så lidt 😉

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #109

            Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma https://www.onclive.com/view/epcoritamab-plus-rituximab-lenalidomide-produces-responses-in-high-risk-r-r-follicular-lymphoma (this was the oral presentation)

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #110

              Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.7506?af=R

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #111

                so the first article is the new/later cutoff date of January 31, 2023; results very similar

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #112

                  104 efficacy evaluable patients treated with epcoritamab at 48 mg plus R2, the overall response rate (ORR) was 98% (median follow-up, 11.4 months). The complete metabolic response (CMR) was
                  87%

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #113

                    (versus the the immediate prior therapy they progressed on,
                    85% and 58% respectively)

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #114

                      easier article maybe - Positive Responses Seen in Follicular Lymphoma When Epcoritamab Is Added to Rituximab and Lenalidomide https://dailynews.ascopubs.org/do/positive-responses-seen-follicular-lymphoma-epcoritamab-added-rituximab-and

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #115

                        As far as I remember Genmab was planning to file epco for approval in FL this year. But I don’t remember if it was RR or 1L. Do you?

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #116

                          oh good question, i had assumed RR as that is usually the case for a first approval
                          ...

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #117

                            Godmorgen 🙂

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Stroka
                              wrote on sidst redigeret af
                              #118

                              God morgen 🙂

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #119

                                Shortpositioner på danske aktier https://www.proinvestor.com/boards/113022

                                1 Reply Last reply
                                0
                                • K Offline
                                  K Offline
                                  Klarussen
                                  wrote on sidst redigeret af
                                  #120

                                  Short Genmab stabil 0,43%, fint, fint. Og det gode ved shorts er jo at de skal købes tilbage på et tidspunkt som Buffet siger 😉

                                  1 Reply Last reply
                                  0
                                  • A Offline
                                    A Offline
                                    AaBforever
                                    wrote on sidst redigeret af
                                    #121

                                    Ja spændende hvornår turen op til 3500 starter...;-)

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Riis7
                                      wrote on sidst redigeret af
                                      #122

                                      Buffet køber ikke aktier unden udbytte og aktietilbagekøbs program:-) Genmabs aktietilbagekøbs program er kun til deres medarbejder:-)

                                      1 Reply Last reply
                                      0
                                      • StockBullS Offline
                                        StockBullS Offline
                                        StockBull
                                        wrote on sidst redigeret af
                                        #123

                                        Den startede i 2010 men som med kurs 2000 tager det også lidt tid at bryde 3000 niveau. Den gode nyhed er 4000 og 5000 kommer til at gå hurtigere så længe de fortsætter med +35% årlig vækst

                                        1 Reply Last reply
                                        0
                                        • StockBullS Offline
                                          StockBullS Offline
                                          StockBull
                                          wrote on sidst redigeret af
                                          #124

                                          Derudover var der jo retracement ned til 2403 så det er vel det sidste bundniveau efter vi var i ATH. Så omkring September burde kursen gå i ny ath hvis det går som det plejer.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper